Amplia Therapeutics (ASX:ATX) said initiation activities for its pancreatic cancer trial in the US have started, focusing on the combination of the company's focal adhesion kinase inhibitor narmafotinib with chemotherapy Folfirinox for advanced pancreatic cancer patients, according to a Wednesday filing with the Australian bourse.
The company partnered with a contract research organization to manage clinical trial activities in the US, the filing said.
The trial will be run under the investigational new drug application for narmafotinib which was cleared by the US Food and Drug Administration, per the filing.
Shares rose nearly 2% in recent trade Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。